Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.43 INR | +0.59% | -.--% | -21.15% |
2022 | R J Biotech Limited Auditor Raises 'Going Concern' Doubt | CI |
2022 | R J Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2022 | CI |
Valuation
Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 236.7 | 232 | 182.7 | 122.1 | 63.72 | 48.95 |
Enterprise Value (EV) 1 | 532.6 | 604.7 | 597.5 | 543.1 | 468.6 | 560.2 |
P/E ratio | -1.58 x | -1.12 x | -1.58 x | -2.94 x | -0.41 x | -0.53 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 1.5 x | 2.61 x | 1.81 x | 0.91 x | 0.4 x | 0.35 x |
EV / Revenue | 3.38 x | 6.8 x | 5.91 x | 4.06 x | 2.97 x | 4.03 x |
EV / EBITDA | -4.73 x | -7.67 x | -8.25 x | -16.1 x | -3.71 x | 28.2 x |
EV / FCF | 59.1 x | 10.6 x | 446 x | 84 x | 5.7 x | -12.9 x |
FCF Yield | 1.69% | 9.43% | 0.22% | 1.19% | 17.5% | -7.76% |
Price to Book | 2.16 x | -2.36 x | -0.86 x | -0.48 x | -0.15 x | -0.1 x |
Nbr of stocks (in thousands) | 9,468 | 9,468 | 9,468 | 9,468 | 9,468 | 9,468 |
Reference price 2 | 25.00 | 24.50 | 19.30 | 12.90 | 6.730 | 5.170 |
Announcement Date | 10/1/17 | 10/10/18 | 9/7/19 | 9/3/20 | 9/9/21 | 8/29/22 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 157.4 | 88.87 | 101.2 | 133.8 | 158 | 139 |
EBITDA 1 | -112.7 | -78.87 | -72.46 | -33.68 | -126.2 | 19.84 |
EBIT 1 | -114.7 | -80.74 | -73.95 | -34.65 | -127.1 | 19.17 |
Operating Margin | -72.9% | -90.84% | -73.1% | -25.89% | -80.46% | 13.79% |
Earnings before Tax (EBT) 1 | -150.2 | -207.7 | -115.3 | -41.56 | -156.8 | -91.58 |
Net income 1 | -150.2 | -207.7 | -115.3 | -41.56 | -156.8 | -91.58 |
Net margin | -95.42% | -233.67% | -113.98% | -31.06% | -99.28% | -65.9% |
EPS 2 | -15.86 | -21.93 | -12.18 | -4.390 | -16.56 | -9.673 |
Free Cash Flow 1 | 9.013 | 57.01 | 1.339 | 6.463 | 82.19 | -43.45 |
FCF margin | 5.73% | 64.15% | 1.32% | 4.83% | 52.04% | -31.27% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 10/1/17 | 10/10/18 | 9/7/19 | 9/3/20 | 9/9/21 | 8/29/22 |
Balance Sheet Analysis
Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 296 | 373 | 415 | 421 | 405 | 511 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -2.626 x | -4.726 x | -5.724 x | -12.5 x | -3.208 x | 25.77 x |
Free Cash Flow 1 | 9.01 | 57 | 1.34 | 6.46 | 82.2 | -43.5 |
ROE (net income / shareholders' equity) | -81.3% | -3,645% | 74% | 17.7% | 47% | 20% |
ROA (Net income/ Total Assets) | -13.4% | -12.2% | -14.7% | -8.14% | -50.8% | 30.8% |
Assets 1 | 1,125 | 1,700 | 784.1 | 510.5 | 308.7 | -297.4 |
Book Value Per Share 2 | 11.60 | -10.40 | -22.50 | -26.90 | -43.50 | -53.20 |
Cash Flow per Share 2 | 0.0400 | -0.0200 | 0.0200 | -0 | 0.0500 | 0.0100 |
Capex 1 | 0.94 | 1.18 | 0.68 | 0.66 | 1.15 | - |
Capex / Sales | 0.59% | 1.33% | 0.67% | 0.49% | 0.73% | - |
Announcement Date | 10/1/17 | 10/10/18 | 9/7/19 | 9/3/20 | 9/9/21 | 8/29/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- RJBIOTECH6 Stock
- Financials R J Bio-Tech Limited